IL17A and colorectal carcinoma: This aligns with efforts by others to overcome immunotherapy resistance in MSS CRC, such as those by Liu et al., who showed that IL-17A inhibition enhances anti-PD-1 efficacy (37), and Wang H. et al., who identified GBP2 as a promising ICB combination target (8).